Imaging Agent News Today

A West Michigan man with pancreatic cancer was the first person in the world to test a new imaging agent, BAMF Health says.

Bawendi’s expertise in optics, fluorescent molecules and tissue imaging were instrumental in development of Lumicell Direct Visualization System, which is currently under FDA review

The new imaging agent Cytalux will now improve the accuracy of lung cancer tumour removal surgery. Imaging Agent Helps to Remove Lung Cancer Tumors: Study.

SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, will be commercially manufacturing and distributing PYLARIFY®(piflufolastat F 18) injection, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. With the recent announcement of the U.S. Food and Drug Administration (FDA) approval, SOFIE will provide a dependable and scalable manufacturing and distribution network to sup...

Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates First Patient Dosed in Validive ® Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021 Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Surgery WILMETTE, Ill., May 13, 2021 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to...

Researchers use imaging agent that enables better monitoring of patients with bacterial infections ANI | Updated: Apr 16, 2021 08:24 IST Washington [US], April 16 (ANI): An imaging agent allows scientists to better visualize Enterobacterales infections in patients, helping to address pathogens that can be life-threatening and frequently resist antibiotics. The agent was safe in 26 patients and differentiated infections from either sterile inflammation or CO...

Published: Mar 15, 2021 March 15, 2021 11:00 UTC Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for the Company’s Lead Product Candidate Vicineum™ Strengthened balance sheet: $98 million in cash and cash equivalents as of February 28, 2021 1 Marketing Authorization Application submitted in Europe with potential approval in early 2022     Sesen Bio (Nasdaq: SESN), a late-stage clinical company developi...